胃癌腹腔分子残留病灶的诊断方法

Diagnostic methods for peritoneal molecular residual disease in gastric cancer

腹膜转移是胃癌最常见的转移形式,是主要致死原因之一。部分患者在手术时往往存在腹腔微小转移灶,这会导致胃癌患者术后的复发转移,因此要积极开展胃癌腹膜转移的防治。分子残留病灶是指经过治疗后,传统影像学或其他实验室方法不能发现,但可通过液体活检发现的肿瘤来源分子异常,代表肿瘤持续存在和临床进展的可能。近年来,基于循环肿瘤DNA检测分子残留病灶逐渐成为了腹膜转移防治领域的研究热点。本课题组建立了胃癌分子残留病灶分子诊断的新方法,并对该领域研究成果进行了评析。

Peritoneal metastasis of gastric cancer serving as the most frequent form of metastasis,is one of the leading causes of death.A portion of surgically treated patients often suffer from small peritoneal residual metastasis,which will lead to recurrence and metastasis of gastric cancer patients after surgery.Given these,the prevention and treatment of peritoneal metastasis of gastric cancer deserves more attention.Molecular residual disease(MRD)refers to the molecular abnormalities of tumor origin that cannot be found by traditional imaging or other laboratory methods after treatment,but can be found by liquid biopsy,representing the possibility of tumor persistence or clinical progress.In recent years,the detection of MRD based on ctDNA has gradually become a research hotspot in the prevention and treatment of peritoneal metastasis.Our team established a new method for MRD molecular diagnosis of gastric cancer,and reviewed the research achievements in this field.